News for ARFXF Stock

ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results ProMIS Neurosciences Presents at 2022 Alzheimer’s Association International Conference ProMIS Neurosciences to Present at 2022 Alzheimer’s Association International Conference ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN” PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application ProMIS Neurosciences Announces Debt Amendment and Conversion ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares ProMIS Neurosciences presents at the 2022 Neuro4D International Conference CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved ProMIS Neurosciences Announces First Quarter 2022 Results ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS) ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF) ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders ProMIS Neurosciences Announces Fiscal Year 2021 Results ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference ProMIS Neurosciences Issues Chairman’s Memorandum ProMIS Neurosciences Shareholders Approve Special Resolution ProMIS Neurosciences Announces Third Quarter 2021 Results ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors ProMIS Neurosciences Announces Update to Senior Management Team ProMIS Neurosciences Files Special Meeting Proxy Material ProMIS Neurosciences Announces Special Shareholder Meeting ProMIS Neurosciences to Present at the Second Annual Undruggable Leaders Forum, September 15-16, 2021 ProMIS Neurosciences to Participate in H.C. Wainwright & Co. 23rd Annual Investment Conference ProMIS Neurosciences appoints accomplished biotechnology executive, Josh Mandel-Brehm, to its Board of Directors ProMIS Neurosciences Closes Upsized US$20,125,000 Public Offering ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M ProMIS Neurosciences Inc. Announces Pricing of US$15 Million Public Offering of Units ProMIS Neurosciences Inc. Announces US$15 Million Offering of Units ProMIS Neurosciences Announces Second Quarter 2021 Results ProMIS Neurosciences Issues Chairman’s Memorandum ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders ProMIS Neurosciences congratulates Biogen on FDA accelerated approval of aducanumab for Alzheimer’s disease ProMIS Neurosciences Files Preliminary Short Form Base Shelf Prospectus ProMIS Neurosciences appoints renowned scientist, Dr. David Wishart as Chief Physics Officer ProMIS Neurosciences initiates commercialization of COVID-19 serology assay ProMIS Neurosciences re-initiates path to IND for PMN310 with producer cell line development ProMIS Neurosciences appoints accomplished biotechnology executive, Neil Warma, to its Board of Directors ProMIS Neurosciences Announces First Quarter 2021 Results ProMIS Neurosciences appoints renowned neuroscientist, Dr. Rudolph Tanzi, as Chair of Scientific Advisory Board ProMIS Neurosciences Announces Fiscal Year 2020 Results ProMIS Neurosciences Completes US$7M (CDN$8.75M) Financing with Distinguished Group of Boston Based Investors ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference